There is evidence confirming that hormonal treatment with drugs known as aromatase inhibitors (like letrozole) is effective in preventing breast cancer from returning. However, the optimal duration or schedule for this treatment is not currently known. 4800 patients who have already completed 4-6 years of hormonal treatment will take part in SOLE, an international randomised clinical trial, and will receive hormonal treatment with the drug letrozole for a further 5 years. This trial will determine if introducing a treatment gap of 3 months every year, for 5 years has any benefit over continuous treatment for 5 years. |